The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells.

Despite much progress in recent years, the precise signalling events triggered by the vascular-endothelial-growth-factor (VEGF) receptors, fms-like tyrosine kinase (Flt1) and kinase insert domain-containing receptor (KDR), are incompletely defined. Results obtained when Flt1 and KDR are individually expressed in fibroblasts or porcine aortic endothelial cells have not been entirely consistent with those observed in other endothelial cells expressing both receptors endogenously. It has also been difficult to demonstrate VEGF-induced phosphorylation of Flt1, which has led to speculation that KDR may be the more important receptor for the mitogenic action of VEGF on endothelial cells. In an attempt to identify physiologically important effectors which bind to KDR, we have screened a yeast two-hybrid mouse embryo library with the cytoplasmic domain of KDR. Here we describe the identification of the adaptor protein, Shc-like protein (Sck), as a binding partner for KDR. We demonstrate that this interaction requires phosphorylation of KDR, and identify the binding site for the Src-homology 2 (SH2) domain as tyrosine-1175 of KDR. We have also shown that the SH2 domain of Sck, but not that of Src-homology collagen protein (Shc), can precipitate phosphorylated KDR from VEGF-stimulated porcine aortic endothelial cells expressing KDR, and that an N-terminally truncated Sck protein can associate with KDR, in a phosphorylation-dependent fashion, when co-expressed in human embryonic kidney 293 cells. Furthermore, we demonstrate that in the two-hybrid assay, both Shc and Sck SH2 domains can associate with the related receptor Flt1.

[1]  D. Gospodarowicz,et al.  Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT‐20 cells. , 1989, The EMBO journal.

[2]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[3]  Yihai Cao,et al.  Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1 , 1998, Oncogene.

[4]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[5]  H. Schägger,et al.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. , 1987, Analytical biochemistry.

[6]  K. Igarashi,et al.  Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2. , 1998, Biochemical and biophysical research communications.

[7]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[8]  C. Wernstedt,et al.  Identification of Vascular Endothelial Growth Factor Receptor-1 Tyrosine Phosphorylation Sites and Binding of SH2 Domain-containing Molecules* , 1998, The Journal of Biological Chemistry.

[9]  J. Folkman,et al.  Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[10]  B. Terman,et al.  Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization , 1999, Oncogene.

[11]  M. Waxham,et al.  Interaction of the Flt-1 Tyrosine Kinase Receptor with the p85 Subunit of Phosphatidylinositol 3-Kinase , 1995, The Journal of Biological Chemistry.

[12]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[13]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[14]  D. Donner,et al.  Vascular Endothelial Cell Growth Factor Promotes Tyrosine Phosphorylation of Mediators of Signal Transduction That Contain SH2 Domains , 1995, The Journal of Biological Chemistry.

[15]  T. Pawson,et al.  A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction , 1992, Cell.

[16]  T. Quinn,et al.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Williams,et al.  An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. , 1994, Science.

[18]  D. Connolly,et al.  Human vascular permeability factor. Isolation from U937 cells. , 1989, The Journal of biological chemistry.

[19]  B. Terman,et al.  Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. , 1994, Biochemical and biophysical research communications.

[20]  M. Shibuya,et al.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. , 1995, Oncogene.

[21]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  T. Pawson,et al.  A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Waxham,et al.  Interactions of FLT-1 and KDR with phospholipase C gamma: identification of the phosphotyrosine binding sites. , 1997, Biochemical and biophysical research communications.

[24]  A. Ullrich,et al.  Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. , 1996, Cancer research.

[25]  C. Auffray,et al.  The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression. , 1996, Genomics.

[26]  K. Igarashi,et al.  Sck interacts with KDR and Flt-1 via its SH2 domain. , 1998, Biochemical and biophysical research communications.

[27]  D. Connolly,et al.  Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. , 1989, The Journal of clinical investigation.

[28]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[29]  Takeshi Nakamura,et al.  N-Shc and Sck, Two Neuronally Expressed Shc Adapter Homologs , 1998, The Journal of Biological Chemistry.

[30]  P. Pandolfi,et al.  A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. , 1996, Oncogene.

[31]  Jonathan A. Cooper,et al.  Mammalian Ras interacts directly with the serine/threonine kinase raf , 1993, Cell.

[32]  W. Gullick,et al.  Binding of Shc to the NPXY Motif Is Mediated by Its N-terminal Domain (*) , 1995, The Journal of Biological Chemistry.

[33]  G. Breier,et al.  The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities , 1996, The Journal of Biological Chemistry.

[34]  M. Shibuya,et al.  The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts , 1997, Oncogene.

[35]  M. Oishi,et al.  N-Shc: a neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway. , 1996, Oncogene.

[36]  R. Sternglanz,et al.  Identification of a new family of tissue-specific basic helix-loop-helix proteins with a two-hybrid system , 1995, Molecular and cellular biology.

[37]  Vishva Dixit,et al.  Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway , 1998, The Journal of Biological Chemistry.

[38]  I. Zachary,et al.  Vascular Endothelial Growth Factor Stimulates Tyrosine Phosphorylation and Recruitment to New Focal Adhesions of Focal Adhesion Kinase and Paxillin in Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[39]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[40]  R. Hungate,et al.  Vascular Endothelial Growth Factor Receptor KDR Tyrosine Kinase Activity Is Increased by Autophosphorylation of Two Activation Loop Tyrosine Residues* , 1999, The Journal of Biological Chemistry.

[41]  G. Thakker,et al.  The Role of Phosphatidylinositol 3-Kinase in Vascular Endothelial Growth Factor Signaling* , 1999, The Journal of Biological Chemistry.

[42]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[43]  M. Shibuya,et al.  A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). , 1994, Oncogene.

[44]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[45]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.